HCPCS code J9289: Nivolumab-hyaluronidase, per 2 mg2026 Medicare rate & RVUs in New York

CMS doesn’t publish an office rate for J9289 in New York.

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9289 covers

J9289 identifies the subcutaneous nivolumab and hyaluronidase-nvhy product marketed as Opdivo Qvantig. Oncology clinicians use it for patients receiving a prescribed subcutaneous nivolumab cancer regimen. A healthcare professional administers the product by subcutaneous injection in an oncology clinic or other treatment setting. The code identifies the drug product and dose, rather than the injection service.

Each billing unit represents 2 mg of nivolumab, so units are calculated from the amount administered using that unit size. CMS assigns physician fee schedule status E, excluding the drug from the physician fee schedule; when Medicare covers it, payment is made under another method. CMS identifies it as a Part B drug, generally priced from its quarterly Average Sales Price files when covered. The Medicare contractor determines coverage.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9289 pays more and less in New York

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

How the J9289 rate is calculated

Each of J9289’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9289

J9289 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9289 compared with similar codes

How to choose

J9299NivolumabPer 1 mg

Use J9289 for subcutaneous nivolumab with hyaluronidase-nvhy. J9299 identifies nivolumab without that combination formulation.

J9298Nivolumab-relatlimabPer 3 mg/1 mg

J9298 identifies nivolumab combined with relatlimab. J9289 identifies nivolumab with hyaluronidase-nvhy, not the relatlimab combination.

J9277Pembrolizumab injectionWith hyaluronidase, per 1 mg

J9277 is subcutaneous pembrolizumab with hyaluronidase; J9289 is subcutaneous nivolumab with hyaluronidase-nvhy.

J9271PembrolizumabPer 1 mg

J9271 identifies pembrolizumab injection, not nivolumab. Choose based on the drug administered, not simply the cancer treatment setting.

Codes related to J9289

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates